These expressions however cannot be directly compared as Rao et al. did not only use CTCs from prostate cancer patients, while they also used a minimal EpCAM expression threshold in their CTC selection, effectively excluding any EpCAM negative CTCs. This evidence concerns the gene EPCAM and prostate carcinoma.